Calls for action

As part of its work, ORSZCA tries to hold organisations to account for their activity (or inactivity) in the area of diarrhoea treatment. Below is a list of our current calls to action and those that have been successfully concluded.

Current calls for action

1. Encourage and support a joint policy briefing by WHO and UNICEF on the co-packaging of ORS and zinc.

A joint statement was being worked on following the introduction of the co-packaging in the 2019 edition of the WHO Essential Medicines List. However, the COVID-19 pandemic meant it had to be dropped.

The objective of such a policy briefing, which would go to all WHO and UNICEF Country Offices, would be to raise awareness of the new co-packaging recommendation in the expectation that this would help with the institutionalisation of co-packaging at the country level.

WHO and UNICEF representatives met initially to discuss this ORSZCA call for action on 16-Feb-2023 and subsequently ORSZCA met with the WHO representative on 22-Feb-2023. Following this meeting ORSZCA has produced a Position Paper on: Defining an ORS/Zinc ‘co-pack’ – comments on this are welcome. On 28 April 2024 WHO/UNICEF posed a set a questions in relation to a joint policy brief which ORSZCA answered in May-2024. These have been commented on by WHO and UNICEF and ORSZCA has responded to these comments.

We now await a further response from WHO/UNICEF.

2. ORSZCA Members – please contribute to our perpetual effort to maintain a picture of the ORS and Zinc status around the world.

We ask members to contribute through our simple questionnaires in English or French. As questionnaires come in we update our status pages here: ORS & Zinc status around the world.

3. DHS/USAID – engage with the next review of the DHS Questionnaires to incorporate questions around co-packaging.

ORSZCA wishes to institutionalise the monitoring of the uptake of co-packaged ORS/Zinc. One way of doing this would be to update the appropriate DHS template questionnaire. This will require ORSZCA to engage with the next DHS review process which was due to start in Sep-2023. We now believe this will take place in early 2025 and we are working to ensure we are included in this review process.
Our focus will be on the current Question 615 in the Woman’s Questionnaire:
Q. 615: SPECIAL FLUIDS AND ZINC
Women are asked if they gave a child with diarrhea fluid made from a packet of oral rehydration salts (ORS) such as [LOCAL NAME FOR ORS PACKET], a pre-packaged ORS liquid such as [LOCAL NAME FOR PRE-PACKAGED ORS LIQUIDS], zinc tablets or syrup, or [a government- recommended homemade fluid]. Read out each item and record the answer given for each one.
Source: https://dhsprogram.com/pubs/pdf/DHSM1/DHS8-Interviewer’s-Manual-EN-07Jan2022.pdf (page 103).
We’d like to change this, or split it into two questions to establish the uptake of co-packaging.

 

Past calls for action

1. UNICEF Co-pack pricing.

This was a three year campaign. It began at the end of 2021 when we noted that the pricing in the UNICEF catalogue for co-packs indicated that it was more than twice as expensive to deliver the recommended treatment for diarrhoea using a co-pack. In September 2021 a co-pack consisting of 1 L ORS sachets and 10 Zinc tablets cost more than twice as much as the separate components from the same catalogue. This is in stark contrast to  the wider market where co-packs tend to be cheaper than buying ORS and Zinc separately.

Our concern was that these high co-pack prices, relative to the price of ORS and Zinc separately, would be a barrier to the uptake of co-packaging.

Initially we  suggested to UNICEF how they might explain more clearly in their catalogue that their indicative price would only be paid by clients ordering from the Copenhagen warehouse today. The majority of the ORS and zinc supplied by UNICEF is not supplied from Copenhagen so these indicative prices do not apply.

Despite on-going email exchanges with UNICEF’s Medicines and nutrition Centre no progress was made.  In February 2024 we escalated the issue to the Director of Supply Division and in the subsequent email exchanges we suggested that the indicative price for co-packs be removed altogether and only be available on request. In October 2024, UNICEF implemented this suggestion. As a result of this we believe:

  • Co-pack enquiry levels will increase (interested parties will not immediately dismiss co-packs due to the very high indicative price)
  • Many orders flowing from enquiries will be fulfilled through direct supply – an arrangement which will have its own price associated with it which is likely to be lower than the UNICEF Catalogue indicative price for items supplied from Copenhagen
  • More cases will be treated with both ORS and Zinc (coverage rate will go up) > mortality and morbidity will reduce

We understand that UNICEF is only one player in this field but they are the most influential one and having prices in their catalogue that indicate that is is much more expensive to use co-packs did not reflect the situation in the wider market and was a barrier to the uptake of co-packs.

We applaud UNICEF Supply Division on this action.

2. World Bank / GFF “Reclaim the Gains” initiative failed to mention Zinc as a component of diarrhoea treatment.

We were very excited when GFF announced their “Reclaim the Gains” initiative which included the objective of an additional 458 million treatments for diarrhoea. However, the original announcement only contemplated treatment with ORS only. we opened discussions on this with the GFF Team and are pleased that they changed the programme objectives to: 458 million treatments for diarrhoea with ORS and Zinc. There is more on this story here.

3. Call to UNICEF and Save the Children to properly reflect the current diarrhoea treatment guidelines in their Child Health Spotlights resource.

On 23-Jan-23 a new version of the Child Health Spotlights website was launched and the “Diagnose & Treat” section for each country is now compatible with the global recommendations. Item 2 reads:

2. access to ORS and Zinc (preferably co-packaged when dispensed for use in the home) as a lifesaving essential and effective treatment for diarrhoea.

We are grateful that this change has been made. However, there are further changes we would like to see and these are:

The incorporation of the ORS/Zinc coverage rates for each country.

These are available from the following UNICEF sources:
https://data.unicef.org/topic/child-health/diarrhoeal-disease/
and
https://data.unicef.org/wp-content/uploads/2018/06/Child-Health-Coverage-Database-May-2022.xlsx

Inclusion of all Top-10 high diarrhoea burden countries in the country look-ups

Currently Cameroon and Madagascar are missing.

Change to the download PDF feature

The ability to download different data analyses for different countries is useful. However, the downloads do not have a country label and so might cause confusion when shared or when doing multiple downloads.

 

Making co-packaged ORS and Zinc the "go to" treatment for childhood diarrhoea

English